Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Corrigendum to 'Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure' [Int. J. Cardiol., Volume 279, 15 March 2019, Pages 141-144].

Bosch L, de Haan JJ, Seijkens TTP, van Tiel CM, Brans MAD, Pasterkamp G, Lutgens E, de Jager SCA.

Int J Cardiol. 2019 Oct 15;293:297. doi: 10.1016/j.ijcard.2019.07.044. Epub 2019 Jul 18. No abstract available.

2.

Nanoparticle-Aided Characterization of Arterial Endothelial Architecture during Atherosclerosis Progression and Metabolic Therapy.

Beldman TJ, Malinova TS, Desclos E, Grootemaat AE, Misiak ALS, van der Velden S, van Roomen CPAA, Beckers L, van Veen HA, Krawczyk PM, Hoebe RA, Sluimer JC, Neele AE, de Winther MPJ, van der Wel NN, Lutgens E, Mulder WJM, Huveneers S, Kluza E.

ACS Nano. 2019 Jul 10. doi: 10.1021/acsnano.8b08875. [Epub ahead of print]

PMID:
31268670
3.

Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology.

Ketelhuth DFJ, Lutgens E, Bäck M, Binder CJ, Van den Bossche J, Daniel C, Dumitriu IE, Hoefer I, Libby P, O'Neill L, Weber C, Evans PC.

Cardiovasc Res. 2019 Jul 1;115(9):1385-1392. doi: 10.1093/cvr/cvz166.

PMID:
31228191
4.

Rational modulator design by exploitation of protein-protein complex structures.

Wichapong K, Poelman H, Ercig B, Hrdinova J, Liu X, Lutgens E, Nicolaes GA.

Future Med Chem. 2019 May;11(9):1015-1033. doi: 10.4155/fmc-2018-0433. Epub 2019 May 29.

PMID:
31141413
5.

Immunotherapy for cardiovascular disease.

Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, Weber C.

Eur Heart J. 2019 May 23. pii: ehz283. doi: 10.1093/eurheartj/ehz283. [Epub ahead of print]

PMID:
31121017
6.

The Link between Hematopoiesis and Atherosclerosis.

de Winther MPJ, Lutgens E.

N Engl J Med. 2019 May 9;380(19):1869-1871. doi: 10.1056/NEJMcibr1901397. No abstract available.

PMID:
31067380
7.

Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death.

Silvestre-Roig C, Braster Q, Wichapong K, Lee EY, Teulon JM, Berrebeh N, Winter J, Adrover JM, Santos GS, Froese A, Lemnitzer P, Ortega-Gómez A, Chevre R, Marschner J, Schumski A, Winter C, Perez-Olivares L, Pan C, Paulin N, Schoufour T, Hartwig H, González-Ramos S, Kamp F, Megens RTA, Mowen KA, Gunzer M, Maegdefessel L, Hackeng T, Lutgens E, Daemen M, von Blume J, Anders HJ, Nikolaev VO, Pellequer JL, Weber C, Hidalgo A, Nicolaes GAF, Wong GCL, Soehnlein O.

Nature. 2019 May;569(7755):236-240. doi: 10.1038/s41586-019-1167-6. Epub 2019 May 1.

PMID:
31043745
8.

Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides.

Neidhart M, Pajak A, Laskari K, Riksen NP, Joosten LAB, Netea MG, Lutgens E, Stroes ESG, Ciurea A, Distler O, Grigorian M, Karouzakis E.

Front Immunol. 2019 Apr 15;10:791. doi: 10.3389/fimmu.2019.00791. eCollection 2019.

9.

Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.

Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TTP, Kroon J, Stroes ESG, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Calcagno C, Fisher EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, Duivenvoorden R.

Nat Biomed Eng. 2018 Aug;2(8):623. doi: 10.1038/s41551-018-0281-3.

PMID:
31015637
10.

Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.

Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TTP, Kroon J, Stroes ESG, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Calcagno C, Fisher EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, Duivenvoorden R.

Nat Biomed Eng. 2018 May;2(5):279-292. doi: 10.1038/s41551-018-0221-2. Epub 2018 Apr 16. Erratum in: Nat Biomed Eng. 2018 Aug;2(8):623.

11.

Germinal Center-Derived Antibodies Promote Atherosclerosis Plaque Size and Stability.

Centa M, Jin H, Hofste L, Hellberg S, Busch A, Baumgartner R, Verzaal NJ, Lind Enoksson S, Perisic Matic L, Boddul SV, Atzler D, Li DY, Sun C, Hansson GK, Ketelhuth DFJ, Hedin U, Wermeling F, Lutgens E, Binder CJ, Maegdesfessel L, Malin SG.

Circulation. 2019 May 21;139(21):2466-2482. doi: 10.1161/CIRCULATIONAHA.118.038534.

PMID:
30894016
12.

Deletion of hematopoietic Dectin-2 or CARD9 does not protect against atherosclerotic plaque formation in hyperlipidemic mice.

Thiem K, Hoeke G, van den Berg S, Hijmans A, Jacobs CWM, Zhou E, Mol IM, Mouktaroudi M, Bussink J, Kanneganti TD, Lutgens E, Stienstra R, Tack CJ, Netea MG, Rensen PCN, Berbée JFP, van Diepen JA.

Sci Rep. 2019 Mar 13;9(1):4337. doi: 10.1038/s41598-019-40663-x.

13.

High Fat Diet Increases Circulating Endocannabinoids Accompanied by Increased Synthesis Enzymes in Adipose Tissue.

Kuipers EN, Kantae V, Maarse BCE, van den Berg SM, van Eenige R, Nahon KJ, Reifel-Miller A, Coskun T, de Winther MPJ, Lutgens E, Kooijman S, Harms AC, Hankemeier T, van der Stelt M, Rensen PCN, Boon MR.

Front Physiol. 2019 Jan 10;9:1913. doi: 10.3389/fphys.2018.01913. eCollection 2018.

14.

Small molecule-mediated inhibition of CD40-TRAF6 reduces adverse cardiac remodelling in pressure overload induced heart failure.

Bosch L, de Haan J, Seijkens T, van Tiel C, Brans M, Pasterkamp G, Lutgens E, de Jager S.

Int J Cardiol. 2019 Mar 15;279:141-144. doi: 10.1016/j.ijcard.2018.12.076. Epub 2018 Dec 28. Erratum in: Int J Cardiol. 2019 Oct 15;293:297.

15.

Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Tuñón J, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Hoefer IE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Bäck M.

Cardiovasc Res. 2019 Jan 1;115(1):10-19. doi: 10.1093/cvr/cvy293.

PMID:
30534957
16.

Scientists on the Spot: Esther Lutgens on the immune system and atherosclerosis.

Patel J, Lutgens E.

Cardiovasc Res. 2018 Dec 1;114(14):e113. doi: 10.1093/cvr/cvy262. No abstract available.

PMID:
30476016
17.

Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis.

Aarts SA, Seijkens TT, Kusters PJ, van Tiel CM, Reiche ME, den Toom M, Beckers L, van Roomen CP, de Winther MP, Kooij G, Lutgens E.

J Pathol. 2019 Apr;247(4):471-480. doi: 10.1002/path.5205. Epub 2019 Jan 30.

18.

A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia.

Baardman J, Verberk SGS, Prange KHM, van Weeghel M, van der Velden S, Ryan DG, Wüst RCI, Neele AE, Speijer D, Denis SW, Witte ME, Houtkooper RH, O'neill LA, Knatko EV, Dinkova-Kostova AT, Lutgens E, de Winther MPJ, Van den Bossche J.

Cell Rep. 2018 Nov 20;25(8):2044-2052.e5. doi: 10.1016/j.celrep.2018.10.092.

19.

Deficiency of the T cell regulator Casitas B-cell lymphoma-B aggravates atherosclerosis by inducing CD8+ T cell-mediated macrophage death.

Seijkens TTP, Poels K, Meiler S, van Tiel CM, Kusters PJH, Reiche M, Atzler D, Winkels H, Tjwa M, Poelman H, Slütter B, Kuiper J, Gijbels M, Kuivenhoven JA, Matic LP, Paulsson-Berne G, Hedin U, Hansson GK, Nicolaes GAF, Daemen MJAP, Weber C, Gerdes N, de Winther MPJ, Lutgens E.

Eur Heart J. 2019 Jan 21;40(4):372-382. doi: 10.1093/eurheartj/ehy714.

20.

Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance.

Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, Conde P, Garcia MR, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM, Ochando J.

Immunity. 2018 Nov 20;49(5):819-828.e6. doi: 10.1016/j.immuni.2018.09.008. Epub 2018 Nov 6.

PMID:
30413362
21.

Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis.

Lacy M, Atzler D, Liu R, de Winther M, Weber C, Lutgens E.

Pharmacol Ther. 2019 Jan;193:50-62. doi: 10.1016/j.pharmthera.2018.08.012. Epub 2018 Aug 25. Review.

PMID:
30149100
22.

Macrophage CD40 plays a minor role in obesity-induced metabolic dysfunction.

Aarts SABM, Reiche ME, den Toom M, Beckers L, Gijbels MJJ, Gerdes N, de Winther MPJ, Lutgens E.

PLoS One. 2018 Aug 10;13(8):e0202150. doi: 10.1371/journal.pone.0202150. eCollection 2018.

23.

Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis.

Seijkens TTP, Lutgens E.

Curr Opin Lipidol. 2018 Oct;29(5):381-388. doi: 10.1097/MOL.0000000000000538.

PMID:
30074493
24.

Circulating levels of P-selectin and E-selectin relate to cardiovascular magnetic resonance-derived aortic characteristics in young adults from the general population, a cross-sectional study.

Eikendal ALM, Bots ML, Gohar A, Lutgens E, Hoefer IE, den Ruijter HM, Leiner T.

J Cardiovasc Magn Reson. 2018 Aug 2;20(1):54. doi: 10.1186/s12968-018-0473-8.

25.

Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology.

Caporali A, Bäck M, Daemen MJ, Hoefer IE, Jones EA, Lutgens E, Matter CM, Bochaton-Piallat ML, Siekmann AF, Sluimer JC, Steffens S, Tuñón J, Vindis C, Wentzel JJ, Ylä-Herttuala S, Evans PC.

Cardiovasc Res. 2018 Sep 1;114(11):1411-1421. doi: 10.1093/cvr/cvy184.

26.

2016 Jeffrey M. Hoeg Award Lecture.

Rouwet E, Lutgens E.

Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1678-1688. doi: 10.1161/ATVBAHA.118.307742. Review.

PMID:
29930003
27.

Commonly available hematological biomarkers are associated with the extent of coronary calcifications.

den Harder AM, de Jong PA, de Groot MCH, Wolterink JM, Budde RPJ, Iŝgum I, van Solinge WW, Ten Berg MJ, Lutgens E, Veldhuis WB, Haitjema S, Hoefer IE, Leiner T.

Atherosclerosis. 2018 Aug;275:166-173. doi: 10.1016/j.atherosclerosis.2018.06.017. Epub 2018 Jun 12.

PMID:
29920437
28.

Myeloid Kdm6b deficiency results in advanced atherosclerosis.

Neele AE, Gijbels MJJ, van der Velden S, Hoeksema MA, Boshuizen MCS, Prange KHM, Chen HJ, Van den Bossche J, van Roomen CPPA, Shami A, Levels JHM, Kroon J, Lucas T, Dimmeler S, Lutgens E, de Winther MPJ.

Atherosclerosis. 2018 Aug;275:156-165. doi: 10.1016/j.atherosclerosis.2018.05.052. Epub 2018 Jun 1.

29.

Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.

Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Francis SE, Ketelhuth DF, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Hoefer IE; ESC Working Group on Atherosclerosis and Vascular Biology.

Eur J Prev Cardiol. 2018 Jun;25(9):948-955. doi: 10.1177/2047487318773384. Epub 2018 May 14.

30.

CD40L Deficiency Protects Against Aneurysm Formation.

Kusters PJH, Seijkens TTP, Beckers L, Lievens D, Winkels H, de Waard V, Duijvestijn A, Lindquist Liljeqvist M, Roy J, Daugherty A, Newby A, Gerdes N, Lutgens E.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1076-1085. doi: 10.1161/ATVBAHA.117.310640. Epub 2018 Mar 8.

PMID:
29519940
31.

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.

Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts SABM, Lameijer M, Gijbels MJ, Beckers L, den Toom M, Slütter B, Kuiper J, Duchene J, Aslani M, Megens RTA, van 't Veer C, Kooij G, Schrijver R, Hoeksema MA, Boon L, Fay F, Tang J, Baxter S, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MPJ, Nicolaes GA, Mulder WJM, Weber C, Lutgens E.

J Am Coll Cardiol. 2018 Feb 6;71(5):527-542. doi: 10.1016/j.jacc.2017.11.055.

32.

The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Aarts SABM, Seijkens TTP, van Dorst KJF, Dijkstra CD, Kooij G, Lutgens E.

Front Immunol. 2017 Dec 12;8:1791. doi: 10.3389/fimmu.2017.01791. eCollection 2017. Review.

33.

Exploring immune checkpoints as potential therapeutic targets in atherosclerosis.

Kusters PJH, Lutgens E, Seijkens TTP.

Cardiovasc Res. 2018 Mar 1;114(3):368-377. doi: 10.1093/cvr/cvx248. Review.

PMID:
29309533
34.

Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques.

Hakimzadeh N, Pinas VA, Molenaar G, de Waard V, Lutgens E, van Eck-Smit BLF, de Bruin K, Piek JJ, Eersels JLH, Booij J, Verberne HJ, Windhorst AD.

PLoS One. 2017 Nov 30;12(11):e0187767. doi: 10.1371/journal.pone.0187767. eCollection 2017.

35.

Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases.

Hoogeveen RM, Nahrendorf M, Riksen NP, Netea MG, de Winther MPJ, Lutgens E, Nordestgaard BG, Neidhart M, Stroes ESG, Catapano AL, Bekkering S.

Eur Heart J. 2018 Oct 7;39(38):3521-3527. doi: 10.1093/eurheartj/ehx581. Erratum in: Eur Heart J. 2018 Jun 14;39(23):2182.

36.

CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice.

Winkels H, Meiler S, Lievens D, Engel D, Spitz C, Bürger C, Beckers L, Dandl A, Reim S, Ahmadsei M, Hartwig H, Holdt LM, Hristov M, Megens RTA, Schmitt MM, Biessen EA, Borst J, Faussner A, Weber C, Lutgens E, Gerdes N.

Eur Heart J. 2017 Dec 21;38(48):3590-3599. doi: 10.1093/eurheartj/ehx517.

PMID:
29045618
37.

CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice.

Steven S, Dib M, Hausding M, Kashani F, Oelze M, Kröller-Schön S, Hanf A, Daub S, Roohani S, Gramlich Y, Lutgens E, Schulz E, Becker C, Lackner KJ, Kleinert H, Knosalla C, Niesler B, Wild PS, Münzel T, Daiber A.

Cardiovasc Res. 2018 Feb 1;114(2):312-323. doi: 10.1093/cvr/cvx197.

PMID:
29036612
38.

Constitutive CD40 Signaling in Dendritic Cells Limits Atherosclerosis by Provoking Inflammatory Bowel Disease and Ensuing Cholesterol Malabsorption.

Kusters P, Seijkens T, Bürger C, Legein B, Winkels H, Gijbels M, Barthels C, Bennett R, Beckers L, Atzler D, Biessen E, Brocker T, Weber C, Gerdes N, Lutgens E.

Am J Pathol. 2017 Dec;187(12):2912-2919. doi: 10.1016/j.ajpath.2017.08.016. Epub 2017 Sep 19.

PMID:
28935569
39.

Helminth antigens counteract a rapid high-fat diet-induced decrease in adipose tissue eosinophils.

van den Berg SM, van Dam AD, Kusters PJH, Beckers L, den Toom M, van der Velden S, Van den Bossche J, van Die I, Boon MR, Rensen PCN, Lutgens E, de Winther MPJ.

J Mol Endocrinol. 2017 Oct;59(3):245-255. doi: 10.1530/JME-17-0112. Epub 2017 Jul 10.

PMID:
28694301
40.

Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology.

Ridger VC, Boulanger CM, Angelillo-Scherrer A, Badimon L, Blanc-Brude O, Bochaton-Piallat ML, Boilard E, Buzas EI, Caporali A, Dignat-George F, Evans PC, Lacroix R, Lutgens E, Ketelhuth DFJ, Nieuwland R, Toti F, Tunon J, Weber C, Hoefer IE.

Thromb Haemost. 2017 Jun 28;117(7):1296-1316. doi: 10.1160/TH16-12-0943. Epub 2017 Jun 1. Review.

41.

Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.

Aarts SABM, Seijkens TTP, Kusters PJH, van der Pol SMA, Zarzycka B, Heijnen PDAM, Beckers L, den Toom M, Gijbels MJJ, Boon L, Weber C, de Vries HE, Nicolaes GAF, Dijkstra CD, Kooij G, Lutgens E.

J Neuroinflammation. 2017 May 12;14(1):105. doi: 10.1186/s12974-017-0875-9.

42.

Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis.

Beldman TJ, Senders ML, Alaarg A, Pérez-Medina C, Tang J, Zhao Y, Fay F, Deichmöller J, Born B, Desclos E, van der Wel NN, Hoebe RA, Kohen F, Kartvelishvily E, Neeman M, Reiner T, Calcagno C, Fayad ZA, de Winther MPJ, Lutgens E, Mulder WJM, Kluza E.

ACS Nano. 2017 Jun 27;11(6):5785-5799. doi: 10.1021/acsnano.7b01385. Epub 2017 May 15.

43.

Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies.

Döring Y, Noels H, van der Vorst EPC, Neideck C, Egea V, Drechsler M, Mandl M, Pawig L, Jansen Y, Schröder K, Bidzhekov K, Megens RTA, Theelen W, Klinkhammer BM, Boor P, Schurgers L, van Gorp R, Ries C, Kusters PJH, van der Wal A, Hackeng TM, Gäbel G, Brandes RP, Soehnlein O, Lutgens E, Vestweber D, Teupser D, Holdt LM, Rader DJ, Saleheen D, Weber C.

Circulation. 2017 Jul 25;136(4):388-403. doi: 10.1161/CIRCULATIONAHA.117.027646. Epub 2017 Apr 27.

44.

Erratum: CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis.

Barthels C, Ogrinc A, Steyer V, Meier S, Simon F, Wimmer M, Blutke A, Straub T, Zimber-Strobl U, Lutgens E, Marconi P, Ohnmacht C, Garzetti D, Stecher B, Brocker T.

Nat Commun. 2017 Apr 24;8:15439. doi: 10.1038/ncomms15439. No abstract available.

45.

Unique properties of thymic antigen-presenting cells promote epigenetic imprinting of alloantigen-specific regulatory T cells.

Garg G, Nikolouli E, Hardtke-Wolenski M, Toker A, Ohkura N, Beckstette M, Miyao T, Geffers R, Floess S, Gerdes N, Lutgens E, Osterloh A, Hori S, Sakaguchi S, Jaeckel E, Huehn J.

Oncotarget. 2017 May 30;8(22):35542-35557. doi: 10.18632/oncotarget.16221.

46.

Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation.

von Hundelshausen P, Agten SM, Eckardt V, Blanchet X, Schmitt MM, Ippel H, Neideck C, Bidzhekov K, Leberzammer J, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen JP, Li H, Ortega-Gomez A, Megens RT, Naumann R, Dijkgraaf I, Nicolaes GA, Döring Y, Soehnlein O, Lutgens E, Heemskerk JW, Koenen RR, Mayo KH, Hackeng TM, Weber C.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaah6650. doi: 10.1126/scitranslmed.aah6650.

PMID:
28381538
47.

Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells.

Neele AE, Prange KH, Hoeksema MA, van der Velden S, Lucas T, Dimmeler S, Lutgens E, Van den Bossche J, de Winther MP.

Epigenomics. 2017 Apr;9(4):383-391. doi: 10.2217/epi-2016-0152. Epub 2017 Mar 21.

PMID:
28322580
48.

CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis.

Barthels C, Ogrinc A, Steyer V, Meier S, Simon F, Wimmer M, Blutke A, Straub T, Zimber-Strobl U, Lutgens E, Marconi P, Ohnmacht C, Garzetti D, Stecher B, Brocker T.

Nat Commun. 2017 Mar 9;8:14715. doi: 10.1038/ncomms14715.

49.

Atherosclerosis: cell biology and lipoproteins focus on epigenetic modification and macrophage biology.

Ferrari E, Lutgens E, Weber C, Gerdes N.

Curr Opin Lipidol. 2017 Apr;28(2):220-221. doi: 10.1097/MOL.0000000000000405. No abstract available.

PMID:
28272157
50.

Inflammation, but not recruitment, of adipose tissue macrophages requires signalling through Mac-1 (CD11b/CD18) in diet-induced obesity (DIO).

Wolf D, Bukosza N, Engel D, Poggi M, Jehle F, Anto Michel N, Chen YC, Colberg C, Hoppe N, Dufner B, Boon L, Blankenbach H, Hilgendorf I, von Zur Muhlen C, Reinöhl J, Sommer B, Marchini T, Febbraio MA, Weber C, Bode C, Peter K, Lutgens E, Zirlik A.

Thromb Haemost. 2017 Jan 26;117(2):325-338. doi: 10.1160/TH16-07-0553. Epub 2016 Nov 17.

PMID:
27853810

Supplemental Content

Loading ...
Support Center